Retatrutide clinical trials
Also written LY3437943.
ClinicalTrials.gov finds 33 studies for retatrutide. How that becomes 33 here
Every study that search finds has been read, to see whether and how it gives retatrutide. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 33Found by its intervention search · See all 33 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 20 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +1Give it under a name that search misses: a biosimilar’s code or a misspelling
- 34Give retatrutide to participants
- −1Observe patients on it, or give it outside a trial
- 33Test it: the count on this site
Get an email when these change. Save the retatrutide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
33 studies that test it; most in 2023 (10)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 10 |
| 2024 | 6 |
| 2025 | 7 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 33 · Other 0
Eli Lilly and Company (32) · Hudson Biotech (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 3 in phase 3
Studies that test retatrutide, phase 3 first.
- Nov 2026A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityPhase 3 · Eli Lilly and Company
- Jun 2027A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightPhase 3 · Eli Lilly and Company
- Sep 2027A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainPhase 3 · Eli Lilly and Company
- Jan 2027A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusPhase 1 · Eli Lilly and Company
- Mar 2027Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are OverweightPhase 2 · Hudson Biotech
Studies
Open first, then newest update. How each study uses retatrutide has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 33
- Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are OverweightRecruitingPhase 2Hudson BiotechNCT07467447Several doses against placebo for weight lossWritten as Retatrutide (LY3437943)Report a problem
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)RecruitingPhase 3Eli Lilly and CompanyNCT07165028Against placebo on liver outcomes in MASLDWritten as RetatrutideReport a problem
- Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06297603Against placebo in type 2 diabetes with kidney impairmentWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightActive, not recruitingPhase 3Eli Lilly and CompanyNCT07232719Against placebo for weight lossWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesCompletedPhase 2Eli Lilly and CompanyNCT05936151Against placebo on kidney function in chronic kidney diseaseWritten as RetatrutideReport a problem
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06383390Against placebo on heart and kidney outcomesWritten as RetatrutideReport a problem
- A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusActive, not recruitingPhase 1Eli Lilly and CompanyNCT06982859Against placebo and semaglutide on insulin secretionWritten as RetatrutideReport a problem
- Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06260722Against semaglutide in type 2 diabetesWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainActive, not recruitingPhase 3Eli Lilly and CompanyNCT07035093Against placebo for chronic low back pain with obesityWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT05929066Against placebo for weight loss, with knee and sleep apnoea subsetsWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT05929079Against placebo for weight loss in type 2 diabetesWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseCompletedPhase 3Eli Lilly and CompanyNCT05882045Against placebo for weight loss with cardiovascular diseaseWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityActive, not recruitingPhase 3Eli Lilly and CompanyNCT06662383Against tirzepatide for weight lossWritten as RetatrutideReport a problem
- A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaCompletedPhase 1Eli Lilly and CompanyNCT06982846Against placebo on recovery from low blood sugarWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightActive, not recruitingPhase 3Eli Lilly and CompanyNCT07357415Three dose escalation schemes comparedWritten as RetatrutideReport a problem
- Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)CompletedPhase 3Eli Lilly and CompanyNCT06354660Against placebo in type 2 diabetes on diet and exerciseWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityActive, not recruitingPhase 3Eli Lilly and CompanyNCT06859268Continued, lowered or stopped to keep weight offWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeCompletedPhase 3Eli Lilly and CompanyNCT05931367Against placebo for knee osteoarthritis pain with obesityWritten as RetatrutideReport a problem
- A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943CompletedPhase 1Eli Lilly and CompanyNCT06313528Against placebo on calorie intake and energy useWritten as LY3437943Report a problem
- To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06808802Its effect on metoprolol levelsWritten as RetatrutideReport a problem
See all 33 studies that test retatrutide →
Tested on its own · 30 — no other medicine in its arm
- Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are OverweightRecruitingPhase 2Hudson BiotechNCT07467447Several doses against placebo for weight lossWritten as Retatrutide (LY3437943)Report a problem
- Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06297603Against placebo in type 2 diabetes with kidney impairmentWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightActive, not recruitingPhase 3Eli Lilly and CompanyNCT07232719Against placebo for weight lossWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesCompletedPhase 2Eli Lilly and CompanyNCT05936151Against placebo on kidney function in chronic kidney diseaseWritten as RetatrutideReport a problem
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06383390Against placebo on heart and kidney outcomesWritten as RetatrutideReport a problem
- A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusActive, not recruitingPhase 1Eli Lilly and CompanyNCT06982859Against placebo and semaglutide on insulin secretionWritten as RetatrutideReport a problem
- Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06260722Against semaglutide in type 2 diabetesWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainActive, not recruitingPhase 3Eli Lilly and CompanyNCT07035093Against placebo for chronic low back pain with obesityWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT05929066Against placebo for weight loss, with knee and sleep apnoea subsetsWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT05929079Against placebo for weight loss in type 2 diabetesWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseCompletedPhase 3Eli Lilly and CompanyNCT05882045Against placebo for weight loss with cardiovascular diseaseWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityActive, not recruitingPhase 3Eli Lilly and CompanyNCT06662383Against tirzepatide for weight lossWritten as RetatrutideReport a problem
- A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaCompletedPhase 1Eli Lilly and CompanyNCT06982846Against placebo on recovery from low blood sugarWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightActive, not recruitingPhase 3Eli Lilly and CompanyNCT07357415Three dose escalation schemes comparedWritten as RetatrutideReport a problem
- Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)CompletedPhase 3Eli Lilly and CompanyNCT06354660Against placebo in type 2 diabetes on diet and exerciseWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityActive, not recruitingPhase 3Eli Lilly and CompanyNCT06859268Continued, lowered or stopped to keep weight offWritten as RetatrutideReport a problem
- A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeCompletedPhase 3Eli Lilly and CompanyNCT05931367Against placebo for knee osteoarthritis pain with obesityWritten as RetatrutideReport a problem
- A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943CompletedPhase 1Eli Lilly and CompanyNCT06313528Against placebo on calorie intake and energy useWritten as LY3437943Report a problem
- A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionCompletedPhase 1Eli Lilly and CompanyNCT05916560Single dose in people with liver impairmentWritten as LY3437943Report a problem
- A Study of LY3437943 in Healthy Participants With a High Body Mass IndexCompletedPhase 1Eli Lilly and CompanyNCT05959096Injection sites and an intravenous dose comparedWritten as LY3437943Report a problem
Showing 20 of 30. See all 30 →
Tested with established drugs · 1 — they are given beside it
Tested in a combination · 2 — another drug in the study is under test too
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)RecruitingPhase 3Eli Lilly and CompanyNCT07165028Against placebo on liver outcomes in MASLDWritten as RetatrutideReport a problem
- A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseCompletedPhase 1Eli Lilly and CompanyNCT06039826Its effect on oral contraceptive levelsWritten as LY3437943Report a problem
Observed · 1 — patients on it are followed, or it is given outside a trial
What changed recently
From the registry's own updates since Oct 18, 2026.
Codes
What other systems call retatrutide · ClinicalTrials.gg INT002054
- MeSH (NLM) C000729679retatrutideOne source ClinicalTrials.gov
- UNII (FDA) NOP2Y096GVRETATRUTIDEConfirmed FDA, Wikidata
- Wikidata Q120468350retatrutideConfirmed FDA, Wikidata
- NCI Thesaurus C190758RetatrutideConfirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729679 | retatrutide | One source ClinicalTrials.gov |
| UNII (FDA) | NOP2Y096GV | RETATRUTIDE | Confirmed FDA, Wikidata |
| Wikidata | Q120468350 | retatrutide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C190758 | Retatrutide | Confirmed FDA, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.